51 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings? http://www.zacks.com/stock/news/575739/whats-in-the-cards-for-astrazeneca-azn-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-575739 Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More http://www.zacks.com/stock/news/453588/busy-morning-for-investors-trade-data-earnings-for-pfe-mrk-cop-more?cid=CS-ZC-FT-ahead_of_wall_street-453588 Jul 30, 2019 - Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails http://www.zacks.com/stock/news/495982/abbvie-ends-rova-t-program-as-3rd-lung-cancer-study-fails?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-495982 Aug 30, 2019 - IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer http://www.zacks.com/stock/news/503040/mercks-keytruda-combination-gets-ec-nod-for-kidney-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503040 Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/505009/roches-tecentriq-combo-gets-eu-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505009 Sep 06, 2019 - The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study http://www.zacks.com/stock/news/505271/bristol-myers-bmy-opdivo-falls-flat-in-brain-tumor-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505271 Sep 06, 2019 - Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs http://www.zacks.com/stock/news/505264/pharma-stock-roundup-agns-opioid-settlement-line-extension-nod-in-eu-for-mrk-jnj-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-505264 Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509890 Sep 09, 2019 - Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug http://www.zacks.com/stock/news/514866/roche-rhhby-reports-positive-data-on-tecentriq-ms-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-514866 Sep 12, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) http://www.zacks.com/stock/news/516412/roche-reports-positive-data-on-tecentriq-nmosd-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516412 Sep 13, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.

Pages: 123456

<<<Page 3>